Brooks represents Irvine-based Allergan Inc. in litigation to protect patents for several of the pharmaceutical company's products.
Under the Hatch-Waxman Act, drug manufacturers can get U.S. Food and Drug Administration approval for generic versions of brand-name drugs if they invalidate the original pharmaceutical company's patents.
On Aug. 2, Brooks started a trial in the Eastern District of Texas to protect Allergan's glaucom...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In